The cholesterol-lowering pill may hold the key to eradicating venous thromboembolism (VTE), one of the most preventable causes of hospital deaths, researchers said.
Researchers at Universities of Leicester and Bristol in the UK analysed 36 studies involving more than 3.2 million people as part of new research.
The study provides an "extensive body of evidence on the clinical benefit of statin in the occurrence of VTE."
"These findings underscore a potential beneficial role of statin therapy on VTE in addition to its established role in cardiovascular disease prevention," said Kamlesh Khunti, professor at the University of Leicester.
More From This Section
"Currently, statins are only approved for lipid lowering in the primary and secondary prevention of cardiovascular disease," said lead researcher Setor Kunutsor from University of Bristol.
"However they have shown great promise beyond their established lipid-lowering effects and these include potential beneficial impact on multiple disease conditions," said Kunutsor.
The study was published in the The Lancet Haematology journal.